NCBI
PubMed
A service of the
U.S. National Library of Medicine
and the
National Institutes of Health
My NCBI
[Sign In]
[Register]
All Databases
PubMed
Nucleotide
Protein
Genome
Structure
OMIM
PMC
Journals
Books
Search
Database name
PubMed
Protein
Nucleotide
GSS
EST
Structure
Genome
Books
CancerChromosomes
Conserved Domains
dbGaP
3D Domains
Gene
Genome Project
GENSAT
GEO Profiles
GEO DataSets
HomoloGene
Journals
MeSH
NCBI Web Site
NLM Catalog
OMIA
OMIM
PMC
PopSet
Probe
Protein Clusters
PubChem BioAssay
PubChem Compound
PubChem Substance
SNP
SRA
Taxonomy
ToolKit
ToolKitAll
UniGene
UniSTS
for
Search term
Go
Clear
Advanced Search
Limits
Preview/Index
History
Clipboard
Details
Display
Summary
Brief
Abstract
AbstractPlus
Citation
MEDLINE
XML
UI List
LinkOut
ASN.1
Related Articles
Cited in Books
CancerChrom Links
Domain Links
3D Domain Links
dbGaP Links
GEO DataSet Links
Gene Links
Gene (OMIM) Links
Gene (GeneRIF) Links
Genome Links
Project Links
GENSAT Links
GEO Profile Links
HomoloGene Links
Nucleotide Links
Nucleotide (RefSeq) Links
Nucleotide (Weighted) Links
EST Links
EST (RefSeq) Links
GSS Links
GSS (RefSeq) Links
OMIA Links
OMIM (calculated) Links
OMIM (cited) Links
BioAssay Links
Compound Links
Compound (MeSH Keyword)
Compound (Publisher) Links
Substance Links
Substance (MeSH Keyword)
Substance (Publisher) Links
PMC Links
Cited in PMC
PopSet Links
Probe Links
Protein Links
Protein (RefSeq) Links
Protein (Weighted) Links
Protein Cluster Links
Cited Articles
SNP Links
SNP (Cited)
Structure Links
Taxonomy via GenBank
UniGene Links
UniSTS Links
Show
5
10
20
50
100
200
500
Sort By
Pub Date
First Author
Last Author
Journal
Title
Send to
Text
File
Printer
Clipboard
Collections
E-mail
Order
All: 1
Review: 0
Click to change filter selection through MyNCBI.
1:
J Clin Oncol.
2008 Sep 1;26(25):4144-50.
Related Articles
,
Links
Cost effectiveness of intraperitoneal compared with intravenous chemotherapy for women with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study.
Havrilesky LJ
,
Secord AA
,
Darcy KM
,
Armstrong DK
,
Kulasingam S
;
Gynecologic Oncology Group
.
Department of Obstetrics and Gynecology, Duke University Medical Center, Durham, NC 27710, USA. havri001@mc.duke.edu
PURPOSE: To determine the cost effectiveness of intraperitoneal versus intravenous regimens for adjuvant treatment of optimally resected stage III ovarian cancer. PATIENTS AND METHODS: A decision model was developed to compare the cost effectiveness at 7-, 11.5-, and 35-year horizons of intravenous carboplatin and paclitaxel (IV-CARBO/PAC), intravenous cisplatin and paclitaxel (IV-CIS/PAC), or intravenous paclitaxel followed by intraperitoneal cisplatin and paclitaxel (IP-CIS/PAC). Survival data were from women participating in representative Gynecologic Oncology Group (GOG) protocols. Medicare reimbursement rates and the Agency for Healthcare Research and Quality Database were used to estimate costs for treatment regimens and grade 3 to 4 adverse effects, respectively. RESULTS: Median predicted survival was 66, 57, 51, and 48 months for IP-CIS/PAC, IV-CARBO/PAC, IV-CIS/PAC (GOG 172), or IV-CIS/PAC (GOG 158), respectively. Across a range of analyses, IV-CIS/PAC was more costly and had lower life expectancy than IV-CARBO/PAC. Compared with IV-CARBO/PAC, IP-CIS/PAC had an incremental cost-effectiveness ratio (ICER) of $180,022 per quality-adjusted life year (QALY) saved at a 7-year time horizon, $71,835/QALY at 11.5 years, and $32,053/QALY over a lifetime. Extending the survival advantage of IP-CIS/PAC over 11.5 years and a lifetime results in ICERs of $26,249 and $23,973, respectively. Assuming IP-CIS/PAC and IV-CIS/PAC were equally effective when administered on an outpatient basis, the ICER of IP-CIS/PAC compared with IV-CARBO/PAC was $26,311. CONCLUSION: Inpatient IP-CIS/PAC, while not cost effective compared with IV-CARBO/PAC at 7 years, becomes cost effective if a longer time horizon is modeled and/or a survival benefit can be assumed to persist longer than currently available data. Outpatient IP-CIS/PAC may also be cost effective compared with IV-CARBO/PAC if proven as effective as inpatient IP-CIS/PAC.
Publication Types:
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
PMID: 18757328 [PubMed - indexed for MEDLINE]
Display
Summary
Brief
Abstract
AbstractPlus
Citation
MEDLINE
XML
UI List
LinkOut
ASN.1
Related Articles
Cited in Books
CancerChrom Links
Domain Links
3D Domain Links
dbGaP Links
GEO DataSet Links
Gene Links
Gene (OMIM) Links
Gene (GeneRIF) Links
Genome Links
Project Links
GENSAT Links
GEO Profile Links
HomoloGene Links
Nucleotide Links
Nucleotide (RefSeq) Links
Nucleotide (Weighted) Links
EST Links
EST (RefSeq) Links
GSS Links
GSS (RefSeq) Links
OMIA Links
OMIM (calculated) Links
OMIM (cited) Links
BioAssay Links
Compound Links
Compound (MeSH Keyword)
Compound (Publisher) Links
Substance Links
Substance (MeSH Keyword)
Substance (Publisher) Links
PMC Links
Cited in PMC
PopSet Links
Probe Links
Protein Links
Protein (RefSeq) Links
Protein (Weighted) Links
Protein Cluster Links
Cited Articles
SNP Links
SNP (Cited)
Structure Links
Taxonomy via GenBank
UniGene Links
UniSTS Links
Show
5
10
20
50
100
200
500
Sort By
Pub Date
First Author
Last Author
Journal
Title
Send to
Text
File
Printer
Clipboard
Collections
E-mail
Order
About Entrez
Text Version
Entrez PubMed
Overview
Help
|
FAQ
Tutorials
New/Noteworthy
E-Utilities
PubMed Services
Journals Database
MeSH Database
Single Citation Matcher
Batch Citation Matcher
Clinical Queries
Special Queries
LinkOut
My NCBI
Related Resources
Order Documents
NLM Mobile
NLM Catalog
NLM Gateway
TOXNET
Consumer Health
Clinical Alerts
ClinicalTrials.gov
PubMed Central
Write to the Help Desk
NCBI
|
NLM
|
NIH
Department of Health & Human Services
Privacy Statement
|
Freedom of Information Act
|
Disclaimer